the cause of Asbestos mesothelioma cancer is asbestos exposure, Exposure to Asbestos can lead to chronic lung disease such as asbestosis, lung cancer and mesothelioma. The association between asbestos exposure and bronchogenic carcinoma is now accepted as being causal in nature. There is a typical latency period of approximately 20 years, and the greater of exposure to asbestos, and higher the risk of lung cancer. NIH scientists believe they may have found a way to help ensure the effectiveness of a new mesothelioma drug called SS1P, One for mesothelin recombinant immunotoxin. SS1P contains an antibody fragment which binds to mesothelin specifically, so it will selectively kill mesothelin-expressing tumors. In mesothelioma cells, mesothelin is frequently 'shed' and ends up in the fluid around the lungs, where it is often used to help make a diagnosis. Unfortunately, this 'shedding' reduces the effectiveness of SS1P and other therapies that attempt to use mesothelin to find and target mesothelioma cells with anti-cancer drugs.
The NIH team theorized that, if mesothelin shedding could somehow be reduced, it could greatly improve the effectiveness of SS1P and potentially give mesothelioma patients and their doctors a much-needed new therapy. They pinpointed two gene-regulating proteins - EGF and TIMP-3 - that work through TACE to determine how much and how often mesothelin is shed from the surface of mesothelioma cells. the researchers confirmed that "reducing shedding significantly improved the in vitro cytotoxicity of immunotoxin SS1P".
mesothelin is a cell surface glycoprotein. It is highly expressed in mesothelioma, ovarian cancer and pancreatic cancer. SS1P is an immunotoxin against mesothelin. Preclinical studies have shown, SS1P have anti-tumor effect. Clinical trials have shown, SS1P be used in the retreatment of patients with stage I, 20 cases of mesothelin expression in pleural mesothelioma, ovarian cancer and pancreatic cancer (pancreatic cancer, 1 case). SS1P can make some patients in stable condition, ascites decreased, there is some anti-tumor effect. Adverse reactions including rash, vascular leak syndrome, abdominal pain, pericardial effusion, etc. Mostly via symptomatic remission. Three against mesothelin targeted therapies, including SS1P (CAT-5001) is a recombinant immunotoxin against the mesothelin. MORAb-009, a chimeric anti-mesothelin monoclonal antibody. CRS-207 is a carrier of inactivation of Listeria monocytogenes, it can encoding human mesothelin. These clinical trials will help de termine the treatment of mesothelin as a target for the true role of cancer.
By improving the understanding of how mesothelin shedding works inside cells, the team hopes their findings will strengthen not only SS1P research, but also give a boost to all mesothelin-based mesothelioma targeted therapies.
iAutoblog the premier autoblogger software
